An Assay to Identify Novel Targets and Personalize Combination Anticancer Therapy

Scientists at JHU have developed a pharmacodiagnostic assay to identify relevant targets and direct the design of individual patient combination anticancer therapy. The assay is based on fine needle aspiration of a neoplastic lesion, exposing the acquired materials ex vivo to control media or media with the drug corresponding to the standard of care for the subject's disease, and processing of the material for comparative mRNA analysis. The assay allows one to rationally seek for relevant targets and individualize anticancer therapy by identifying the most adequate combination considering the response of the subject's tumor cells to exposure to the standard treatment, prior to initiation of therapy. Therefore therapy can be tailored specifically for each individual patient, offering each patient the chance of being treated with a wider array of agents in a rational manner. As the assay can be performed with minimal morbidities and discomfort, it can globally improve the safety of cancer treatment. Description (Set) Proposed Use (Set) A rapid, molecular-based assay to be applied to small quantities of tumor tissue for sensitivity testing. The assay can be adapted to many anticancer agents on the market and/or undergoing evaluation in clinical trials.

Inventor(s): Jimeno, Antonio

Type of Offer: Licensing



« More Medical Patents

---